Skip to content
Review

Advances in influenza A and B virus detection: molecular diagnostics, biosensors, and point-of-care applications.

Oct 2026 · Journal of Microbiological Methods · pp. 107746 · 0 citations · 91 references
Medicine

Abstract

Influenza A and B viruses remain major causes of seasonal epidemics and continue to pose substantial challenges for rapid clinical diagnosis and public-health surveillance. Conventional methods, including viral culture, immunological assays, and reverse-transcription real-time quantitative PCR (RT-qPCR), provide important diagnostic benchmarks but are constrained by long turnaround times, dependence on specialized equipment, or reduced sensitivity in low-viral-load specimens. This review summarizes recent advances in influenza virus detection, with emphasis on molecular diagnostics, biosensors, point-of-care testing, and high-throughput sequencing. Digital PCR offers precise absolute quantification, whereas isothermal amplification technologies such as reverse transcription loop-mediated isothermal amplification (RT-LAMP) and reverse transcription recombinase polymerase amplification (RT-RPA) reduce reliance on thermal cycling and support portable testing. CRISPR-Cas systems further improve sequence specificity and are increasingly being integrated with isothermal amplification, lateral-flow readouts, and microfluidic platforms. Biosensor strategies based on optical, electrochemical, multimodal, and smartphone-assisted readouts provide promising routes for rapid, multiplexed, and point-of-care detection, although standardization and large-scale clinical validation remain key barriers. High-throughput sequencing complements rapid testing by enabling viral typing, variant monitoring, and emerging-pathogen monitoring. Overall, future influenza diagnostics are expected to move toward integrated, low-cost, "sample-in, answer-out" systems that combine sensitivity, speed, portability, and surveillance connectivity.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.